Teledyne Technologies Incorporated (NYSE: TDY) — Better Fundamentals, Cheaper Multiple, One Big Integration Test

Independent equity research note. Report date: 2026-09-03. Price reference: $606.36 (2026-09-02 close).

The analytical body below is position-free and contains no buy/sell recommendation or price target. The single exception is the deliberately fenced opinion block immediately below.

⚡ Claude’s Take

The author’s subjective opinion; general information, not investment advice. The analytical body below carries no recommendation.

Verdict: HOLD / selectively accumulate on weakness — the call is more constructive than on 2026-07-04, but $606 still discounts much of the defense-and-space acceleration. A sensible accumulation zone is roughly $540–590 (about 22–24x the midpoint of FY2026 non-GAAP EPS); below roughly $525 the margin of safety becomes compelling. Not a short. Conviction: medium.

Two things changed in opposite directions and both help a prospective holder: operations strengthened while the share price fell. Q2 revenue rose 9.8%, with only $12.2M of acquisition contribution; Digital Imaging grew 11.9% organically; book-to-bill reached 1.23 and the funded order book moved above $5B. Management raised the full-year revenue outlook by $120M and non-GAAP EPS by about 2.3%. Meanwhile TDY fell 7.0% from this report’s prior reference price. At $606, the shares trade near 24.7x the $24.55 midpoint of FY2026 adjusted EPS and roughly 19x trailing EBITDA—still a quality-compounder valuation, but no longer the 27x-forward, top-decile-own-history setup that made $652 unattractive.

The Varex acquisition is the new judgment call. It is large enough to test CEO George Bobb’s allocation discipline, but the preliminary economics are unusually favorable: about $1.1B of enterprise value for roughly $845M of FY2025 revenue and about $120M of trailing adjusted EBITDA, or about 1.3x sales and 9x EBITDA before synergies. That is not the “large and richly priced” deal that would confirm the bear case. The catch is quality: Varex’s medical revenue is declining, inventories are heavy, and its underlying EBITDA is obscured by tariff refunds. TDY now has to prove that a cheap adjacent asset can become a higher-return one. The framing is quality compounder at a less demanding—but not cheap—price, not a falling knife or momentum chase.

What flips the view: bullish if organic growth remains at or above 6% through 2027 while underlying margins and pro-forma ROIC rise after Varex; bearish if book-to-bill falls below 1.0 for two quarters, Varex’s medical decline persists without margin repair, or another large deal arrives before leverage and integration normalize.

🔄 Changes Since the 2026-07-04 Report

The July bull test—sustained 6% organic growth and better group returns—is partly confirmed, not complete: organic growth has cleared the threshold for two quarters, but group ROIC still has to improve. The bear test is not confirmed. Orders remain above sales, and although a major acquisition arrived, its entry multiple is restrained rather than rich. The new falsifiable question is whether Varex’s low purchase multiple survives working-capital cleanup, integration costs and the normalization of tariff-related benefits.

📈 Stock Price Action — Five-Year Event Map

TDY closed at $606.36 on September 2, 2026. Its trailing-52-week intraday range was $483.02 to $697.67, putting the close 13.1% below the August high. The five-year path includes one macro de-rating, several earnings resets and a 2026 defense-led rerating; it is not a smooth compounder chart.

The earnings dates anchor the attributions. The April 2024 move occurred on 1.10M shares versus a roughly 0.23M then-90-day average; the January 21, 2026 FY2025 release produced a 9.8% one-day gain. By contrast, the July 22 Q2 beat-and-raise produced only a 0.5% gain, evidence that high expectations already existed. On August 10, the Varex announcement date, TDY touched the $697.67 intraday high but closed slightly down, then fell 12.2% through September 2. Price history is from the AZI daily-price series, with events cross-referenced to Teledyne SEC filings and the Varex announcement.

1. Executive Summary

Teledyne is a collection of engineering-heavy, low-volume, high-consequence niches: infrared detectors and thermal cameras, scientific imaging sensors, oscilloscopes and protocol analyzers, subsea connectors and instruments, aerospace electronics, and government-engineered systems. Those positions are protected chiefly by qualification histories, embedded application know-how, long product lives and switching risk—not consumer brand or lowest-cost labor. The operating franchises are excellent. The acquisition balance sheet is less exceptional: goodwill and acquired intangibles dominate invested capital, so the high returns visible on tangible operating assets become mid-to-high-single-digit reported returns at the consolidated level.

The near-term operating evidence is the strongest in years. Q2 2026 delivered $1.663B of revenue, up 9.8%; acquired businesses added just $12.2M. GAAP operating margin expanded 160bp to 20.0%, adjusted margin rose 120bp to 23.4%, and adjusted EPS rose 20.8% to $6.28. Digital Imaging was the engine: sales rose 12.7%, 11.9% organically, while space detectors and infrared systems for unmanned/counter-unmanned applications each grew more than 20%. Instrumentation, Aerospace & Defense Electronics and Engineered Systems also grew, making this broader than a single-program spike.

Demand visibility improved as well. Management reported all-time-record quarterly orders, a 1.23 book-to-bill ratio and more than 1.4 in Digital Imaging; the 10-Q disclosed $5.176B of remaining performance obligations, 72% expected within twelve months. Orders have exceeded sales for eleven consecutive quarters. That evidence contradicts the most immediate bear concern—a defense-themed multiple sitting atop fading orders. It does not eliminate program timing, government-budget, export-control or component-supply risks.

Earnings quality is good but requires two normalizations. First, Q2 Digital Imaging margin received about $10M, or 120bp, from net tariff refunds; underlying segment margin still rose more than 200bp. Second, acquired-intangible amortization remains economically relevant even if noncash: it was $113.6M in the first half, up from $106.6M. GAAP net income of $478.5M converted into $549.2M of operating cash flow in the half, and free cash flow rose to $489.0M after $60.2M of capex. The cash engine is real; adjusted earnings are useful for operations but should not be capitalized without acknowledging the price paid for acquired technology and customer relationships.

Capital allocation is now the pivotal issue. Teledyne agreed on August 10 to acquire Varex Imaging for $18.90 per share in cash, about $1.1B including equity awards and net debt, subject to approvals and expected to close in early 2027. Varex extends Teledyne into X-ray tubes, flat-panel and photon-counting detectors, high-voltage interconnects and imaging software. The fit is adjacent, and the entry price—roughly 1.3x FY2025 sales and 9x trailing adjusted EBITDA—is far below the multiple on TDY itself. Yet cheapness is not quality: Varex’s Medical revenue declined in its latest quarter, inventory equaled $347M, and approximately $10M of quarterly profit came from net tariff recoveries. Integration and return improvement, not announced “synergies,” will determine whether the discount was earned.

At $606.36, TDY’s equity value is about $28.1B and enterprise value roughly $29.8B before Varex. The price implies about 24.7x FY2026 adjusted EPS, 29.1x guided GAAP EPS, roughly 19x trailing EBITDA and a 4.1% trailing free-cash-flow yield. These are not distressed expectations. They imply that mid-single-digit-plus organic growth, sustained margin gains and disciplined acquisitions persist. Compared with the July baseline, however, investors are paying a lower multiple for a higher earnings base. The operating thesis strengthened faster than the valuation case deteriorated.

Bottom line: Teledyne’s competitive positions and demand trajectory are stronger than they appeared two months ago. The market still capitalizes a long duration of defense/space growth and competent M&A, while reported ROIC remains the constraint. Varex can narrow that gap because the entry multiple is low, but only if Teledyne repairs the target’s medical growth, working capital and margins without distracting from FLIR. The core debate has shifted from “is the defense wave real?” toward “can the new CEO convert a cheap, larger deal into higher group returns?”

2. Business Overview

What Teledyne is. A diversified technology company that, in its own words, “provides enabling technologies to sense, analyze and distribute information for industrial growth markets that require advanced technology and high reliability” (FY2025 10-K, Item 1). The through-line is high-reliability, high-mix, low-volume hardware for demanding physical/technical environments — not a single product, platform, or recurring-revenue engine. Scale was bought, not built: 75 acquisitions in 25 years for ~$12.8bn, with FLIR (~$8bn, 2021) roughly doubling the company.

Segment structure (FY2025, from the Form 10-K segment MD&A and Note 4):

What each segment does:

• Digital Imaging (52%, FLIR-created). Sensors, cameras and systems across visible / infrared / UV / X-ray, plus MEMS and high-reliability semiconductors. A split personality: commercial machine-vision imagers (Teledyne DALSA / e2v), thermal cores & cameras (Teledyne FLIR), and X-ray on one side; defense EO/IR, lasers/optics/radar, CBRNE detection and unmanned air/ground/sea systems on the other. FY25 grew only +3.0% (commercial IR components +$55.9M, unmanned air +$35.1M, surveillance +$28.7M; offset by IR systems −$25.2M and X-ray −$14.2M). Reported margin 16.7% is depressed by $185.3M of acquired-intangible amortization (5.9% of segment sales) — ex-amortization it runs ~22.6%.
• Instrumentation (24%, the margin king at 27.5%). Marine (subsea connectors/penetrators, sonar, autonomous underwater vehicles — offshore energy, naval, oceanographic); Environmental (air/water/emissions monitoring, lab and gas/flame detection); Test & Measurement (Teledyne LeCroy oscilloscopes and protocol analyzers). FY25 +5.4%, led by marine +$48.6M. The 27.5% margin sits on only ~$13M of amortization (0.9% of sales) — margin earned from product and IP, not accounting.
• Aerospace & Defense Electronics (17%, +36% on Qioptiq). Components and subsystems: harsh-environment interconnects, avionics and data-acquisition systems, general-aviation batteries, satcom. $244.2M of the $281.9M FY25 increase was acquired (Excelitas/Qioptiq). Margin fell to 24.8% (from 28.5%) on inventory step-up and integration costs — a live example of bolt-ons diluting near-term returns before the optimization process runs.
• Engineered Systems (7%, weak at 10.7%). Government-project systems integration, specialty electronics, energy/marine systems for NASA, the Department of Defense and Department of Energy. 84.5% U.S.-Government, 1.3% international; revenue −0.9% and guided to soften on NASA budget pressure. Commodity project work with no pricing power.

How it makes money. Revenue is roughly ~60% point-in-time (short-cycle commercial product sales) and ~40% over-time (cost-to-cost engineered/defense work; Qioptiq lifted the over-time share) — a blend of short-cycle industrial product sales and longer-cycle defense/engineered projects, with no meaningful recurring or aftermarket annuity. Investors should not credit software-like economics here: this is hardware and project revenue. At FY2025 year-end, remaining performance obligations stood at $4,611.7M (0.75x sales), 71% recognizable within 12 months; by June 28 they had risen to $5,176.1M, 72% due within twelve months—solid coverage, but still not a subscription book.

Customer and geographic mix. No commercial customer exceeds 10% of sales; U.S. Government is 25.5% ($1,559.4M; Department of Defense $1,203.6M / ~19.7%), and 81% of U.S.-Government contracts are fixed-price (cost risk on Teledyne). International is ~48% ($2,932.6M across 100+ countries; top-five UK/Germany/Japan/China/France ~20%). Total defense exposure is ~30–35% and rising. Workforce ~15,800 across 38 countries, ~10-year average tenure, ~8% turnover.

The Teledyne model. A decentralized federation run for margin and cash by a long-tenured team: buy niche #1/#2 businesses, integrate onto shared overhead, contain costs, expand margins, and redeploy the cash (FY25 operating cash flow $1,191.3M) across capex, M&A, buybacks and debt reduction. R&D is a moderate ~$317.3M (~5.2% of sales) — this is a buy-and-optimize, not invent-and-scale, business.

Verdict — a well-run, cash-generative, but structurally ordinary hardware federation. Two excellent segments (Instrumentation, A&D), one large-but-mixed (Digital Imaging), one weak (Engineered Systems). Respectable aggregate economics and a genuine cash engine — but product/project hardware, not a recurring annuity, and scale that was bought rather than built. The model works; it is not obviously special.

3. Industry Dynamics

September 2026 update — strong demand, broad cycle, rising supply response. Teledyne’s acceleration is genuine, but the peer tape shows it is not uniquely Teledyne’s. Leonardo DRS reported 10% organic growth, 1.2 book-to-bill and 17% funded-backlog growth; Curtiss-Wright reported 1.16 book-to-bill and 10% backlog growth; AMETEK’s orders rose 28%; Cognex’s machine-vision revenue grew 17%; and Keysight’s quarterly revenue rose 37% with orders above $2B for a second quarter. The common denominator is a simultaneous upturn in defense, automation, semiconductor/test and imaging—not yet evidence that TDY is taking share. That distinction matters because a broad cycle can lift even average competitors and then attract capacity.

The demand runway is unusually visible. The U.S. FY2026 defense-budget request included $25B of initial Golden Dome funding, while the FY2027 Space Force request proposes $71.1B, including $21.6B for space-control systems and $6.7B for satellite communications. Europe’s Readiness 2030 roadmap says its policy levers could mobilize up to €800B of additional defense expenditure and targets at least 55% procurement from the European defense industrial base. These are budgets and policy envelopes, not Teledyne’s addressable market; applying a market-share percentage to them would be false precision. More defensible are management’s own revenue pools: roughly $575M of 2026 unmanned revenue, $400–450M of space revenue and a $200–250M missile-and-munitions run rate.

Marathon capital-cycle read. Returns and order books are attracting investment. Teledyne is raising defense-related capex about 30%, with government and customers co-funding some capacity; peers are expanding too, and the M&A market for qualified sensor assets remains crowded. Long qualification cycles, flight heritage, export licenses and process know-how slow the supply response, but they do not repeal it. The industry is moving from scarcity into investment: excellent for incumbent revenue over the next several years, less obviously excellent for terminal margins and acquisition prices. Europe’s local-content preference also makes Qioptiq’s footprint more valuable while limiting the idea that a U.S. factory can serve every program.

Teledyne plays in roughly a dozen niche end-markets. Two questions matter: is the portfolio of industries attractive, and is the roll-up game that assembles it still favorable? The answers are mixed-to-good on the first and clearly late-cycle on the second.

• Machine vision. Teledyne sells sensors, cameras and acquisition components into a market where Cognex and Keyence capture more software and systems economics. The Q2 recovery was broad, but Cognex’s 17% growth exceeded TDY’s roughly 8% industrial/scientific-vision growth; product scopes differ, so that is a warning against claiming share gain rather than proof of share loss.
• IR, thermal and defense electro-optics. FLIR, Lynred, Leonardo DRS, Northrop and specialist detector makers compete behind meaningful process and qualification barriers. Teledyne is strongest where detector fabrication, cooling, radiation tolerance, export controls and platform history matter.
• Scientific and space sensors. Volumes are small and mission consequences high. Radiation-hardening, flight heritage and long qualification make these among the portfolio’s best niches, though program timing can make revenue lumpy.
• Marine and subsea. Connectors, penetrators, sonar and autonomous vehicles are designed into offshore-energy, naval and oceanographic systems. Switching costs are real, while end demand remains cyclical.
• Environmental instrumentation. Regulation creates recurring replacement and compliance demand, providing ballast against defense and industrial cycles.
• Test and measurement. LeCroy competes with Keysight, Rohde & Schwarz and Tektronix/Ralliant. Protocol-analysis expertise and installed workflows help, but semiconductor and communications development budgets remain cyclical.
• Defense electronics and avionics. Qualification and ITAR/EAR compliance create captivity after design-in, while budgets, primes and platform schedules retain bargaining power.
• Engineered systems. Government project work is the least attractive pool: more bid-based, cost-estimate-sensitive and lower margin.

The defense / drone / counter-drone / space cycle. These are genuine multi-year tailwinds — counter-UAS, EO/IR/ISR, unmanned systems, and space sensing pulled by the Space Development Agency’s tranche architecture and the “Golden Dome” concept. But Teledyne is a components/subsystems supplier, not a prime, so it captures a slice of the wave and remains exposed to appropriations timing, continuing resolutions and shutdown risk.

Regulation. ITAR/EAR is double-edged—a barrier to unqualified entrants and a constraint on where Teledyne can ship dual-use cameras and detector technology. China’s licensing of specified rare-earth materials and magnets constrains inputs, while Europe’s 55% local-procurement target makes manufacturing footprint part of market access. The 81% fixed-price U.S.-government mix shifts cost risk onto Teledyne. The 2026 BIS order shows that legacy and post-acquisition FLIR compliance remain live issues.

Capital-cycle (Marathon lens). The “buy niche instruments and optimize” strategy is no longer proprietary. AMETEK, Roper, Danaher, Halma, Judges Scientific, Fortive/Ralliant and financial sponsors all hunt the same bolt-ons; management concedes rivals have “greater resources than we do” and, tellingly, complains that buyers “are willing to pay some outrageous prices to get the revenue.” High historical returns have attracted capital: quality-instrument multiples now sit in the high-teens/low-20s EV/EBITDA, which is precisely why Teledyne’s incremental ROIC is single-digit. The operating industries remain attractive; the market for buying them is expensive.

Verdict — a structurally good collection of niches entered through an increasingly expensive door. Most of Teledyne’s end-markets are high-barrier, specialized, non-commoditized, and several are oligopolistic (thermal/IR, oscilloscopes, subsea), with real defense/space/counter-UAS tailwinds and defensive environmental demand. But the portfolio is fragmented, cyclically exposed (offshore energy, semis, commercial aero, government budgets), threatened at the edges by subsidized Asian competition and local-content rules, and the roll-up game is crowded and richly priced. Good industries; a poor point in the capital cycle to be the marginal buyer.

4. Competitive Position

Current evidence strengthens the product moats, not a corporate moat. The FY2025 10-K is unusually candid: every market is highly competitive; some rivals have larger installed bases and resources; customers may vertically integrate; and low-cost Chinese competitors are present. In the same filing, Teledyne explains why certain niches remain defensible: changing a designed-in Defense Electronics component can require lengthy and expensive system-level qualification. That is Greenwald-style customer captivity—risk, certification history and engineering retraining make switching uneconomic—not a brand halo or network effect shared across the company.

Q2 segment economics preserve the hierarchy. Digital Imaging’s GAAP margin rose from 15.5% to 19.6%; Aerospace & Defense Electronics reached 26.0%; Instrumentation remained highest-quality at 26.1%; Engineered Systems earned only 12.6%. One important counterexample prevents a simplistic “defense mix equals margin” conclusion: Marine Instrumentation sales rose on offshore-energy and defense products, but segment operating income fell slightly and margin compressed 150bp because autonomous-underwater-vehicle and other marine mix was less favorable. Product and contract mix, not thematic labels, determines the profit pool.

Varex adds a new form of captivity. Its FY2025 10-K reports an installed base above 160,000 X-ray tubes, 170,000 detectors, 600,000 connect/control components and 16,500 software instances. CT tubes are replaced every two to six years—more frequently in high-utilization China—and customized components can be named in regulated OEM registrations, making supplier changes costly and sometimes approval-dependent. That is a real replacement annuity.

It is bilateral captivity, not monopoly. Varex’s top ten customers represented 52% of FY2025 revenue; Canon Medical alone was 18%, and GE, Siemens, United Imaging and Rapiscan sit among the largest accounts. Detector competitors include Trixell, Canon, Vieworks, Hamamatsu, iRay and CareRay; several OEM customers also make tubes internally. The acquisition removes one competitor from Teledyne’s pre-deal industrial X-ray field and adds high-radiation and photon-counting capabilities, but it does not create market control. The moat accretion is real at the product level and constrained by customer concentration and vertical integration.

The central question: is there a company-level moat, or is this a competent conglomerate of decent niches? The evidence points firmly to the latter — the advantages live inside the operating units, and the price paid to assemble them left the enterprise earning roughly its cost of capital.

Moat by segment (Greenwald taxonomy):

• Instrumentation — switching costs + intangibles (genuine). A 27.5% margin on 0.9%-of-sales amortization is product-driven, not accounting-driven. Subsea connectors/penetrators, sonar and LeCroy protocol analyzers are designed-in, qualification-gated and mission-critical. The moat is proven by the financial outcome.
• A&D Electronics — switching costs (program-locked, ITAR-gated). A 24.8% margin from components designed onto multi-year platforms, sole/dual-sourced with long qualification cycles. Sticky, but budget-dependent.
• Digital Imaging — mixed. A real moat in IR (FLIR) and space sensors (e2v) — intangibles plus detector-fab scale and oligopoly. Weak in machine vision (DALSA) — a component supplier against Cognex/Keyence, who own the software and installed base. The blended 16.7% (22.6% ex-amortization) sits below Instrumentation/A&D, revealing diluted pricing power.
• Engineered Systems — no moat. 10.7% margin, 84.5% U.S.-Gov, NASA-hostage, commodity project work.

A corporate moat? No. Management states plainly that “each of our markets is highly competitive … many of our competitors have … greater … resources than we do.” There is no shared customer, no cross-segment network effect, no company-wide scale advantage. The only enterprise-level edge is a capital-allocation and cost-containment culture — a management attribute, copyable by AMETEK/Roper, that does not survive a Greenwald test.

The killer statistic — ROIC vs WACC. Company ROIC was ~7.4% in FY2025 and is about 7.8% TTM (FY2025 ROE about 8.9%) against an estimated ~8–9% WACC: the enterprise, as assembled at the prices paid, earns roughly — or below — its cost of capital. Goodwill of $8,687.6M plus net intangibles of $2,100.1M equals $10.79bn, or 70.6% of total assets — most of the economic rent was capitalized into purchase prices and transferred to sellers. The FLIR fingerprint is unmistakable: ROIC ran 10.9% pre-FLIR (FY2020), fell to 6.6% at close (FY2021), and has been stuck at 6.6–7.8% every year since. A single ~$8bn deal, ~⅔ goodwill/intangibles, roughly halved company ROIC and it has not recovered.

Peer comparison (ROIC.ai, FY2025):

Three conclusions follow. (1) TDY’s 7.4% is not uniquely bad — Roper (6.3%) and Danaher (5.7%) report lower; the whole premium-serial-acquirer cohort earns mid-single-digit ROIC by capitalizing premia. (2) But TDY carries the DHR/ROP-style goodwill drag without their recurring-software or consumables economics — 42.8%-gross-margin hardware is lower-quality collateral for the same balance-sheet load. (3) AMETEK is the standing rebuke: 12.6% ROIC and 25.8% operating margin on lower gross margin, achieved by running leaner and paying disciplined multiples for smaller bolt-ons rather than one $8bn platform.

Verdict — durable niche advantages, no durable company-level moat, returns roughly at cost of capital. Real switching-cost and intangible advantages exist inside Instrumentation, A&D, and the IR/space parts of Digital Imaging (proven by 25–28% segment margins and durable qualification barriers). But there is no scale/network/switching-cost edge at the corporate level; the only company-wide advantage is an operating-discipline culture — a management attribute, not a structural moat. 7.4% ROIC vs ~8–9% WACC is the honest summary: good businesses bought at prices that transferred most of the rent to sellers. AMETEK proves it can be done better; Roper/Danaher prove TDY is not the worst offender. Teledyne sits in the middle — a very good company and an ordinary compounder of capital.

5. Growth History and Forward Opportunities

The 2026 evidence upgrades the organic algorithm—provisionally. Q2 organic growth was about 9.0% by reconciliation: $1.6625B of reported revenue less $12.2M of acquisition contribution against roughly $1.514B in the prior year. For the first half, revenue rose 8.7% while acquisitions added only $25.2M, implying about 7.8% organic growth. That clears the prior memo’s 6% bull marker, but six months is not a through-cycle record. The right conclusion is “tracking,” not “passed.”

Breadth improves the signal. Digital Imaging grew 11.9% organically; space infrared detectors and unmanned/counter-unmanned cameras each grew above 20%; Marine defense products grew around 20%; Qioptiq grew around 20% organically; industrial/scientific vision grew around 8%; healthcare imaging around 8.5%; and test and measurement 4.3%. Management raised FY2026 revenue guidance to more than $6.53B—nearly 7% reported growth—and now expects Digital Imaging, Instrumentation, Aerospace & Defense Electronics and Engineered Systems to grow roughly 7.5%, 5.7%, 7.2% and 5.6%, respectively. That is a much healthier mix than FY2024’s near-stagnation.

The primary-source discipline matters here. Prior third-party market-size estimates for machine vision and electro-optical/infrared systems mixed component and system definitions and are not reproducible; this update does not carry them forward. Teledyne’s disclosed revenue pools and funded backlog provide a cleaner basis. They show meaningful exposure to structurally funded programs without implying that every dollar of Golden Dome or European rearmament is addressable.

Historical growth — a 2021 acquisition step-change, then modest organic. Teledyne’s five-year revenue record is a textbook serial-acquirer signature: one large step-change from a transformational deal, then low-single-digit organic in the intervening years, punctuated by bolt-ons.

The fact the top line hides: two of the five growth years (2021–22) came almost entirely from acquiring FLIR; the three organic years that followed (2023–25) averaged only ~3.9% total revenue growth, and FY2024 was essentially flat. The FLIR-specific interpretation is unflattering: Teledyne paid a full price (~$8bn, mid-teens EV/EBITDA) for a business that had been a serial disappointer under prior management, and IR imaging/surveillance only re-accelerated to >20% growth in 2025 on the European/Ukraine defense wave — the payoff arrived from an exogenous demand shock, not from a Teledyne-specific value-creation lever. The underlying organic algorithm of the whole company is mid-single-digit.

FY2025 composition and Q1-26 momentum. Digital Imaging (52%) +3.0% but with IR components/subsystems +>20% and unmanned air double-digit; Instrumentation +5.4% (marine +8%, subsea AUVs +>20%, environmental +6.7%, but test & measurement −3.7% on the oscilloscope/protocol cycle); A&D +36.3% (largely acquired); Engineered Systems −2.6%/lumpy. The Q1-2026 headline was strong — sales +7.6%, organic +6.9%, non-GAAP EPS +17.2%, book-to-bill 1.16 (tenth consecutive quarter >1), backlog ~$4.6bn.

Forward opportunities.

1. Defense / unmanned / counter-drone — the 2026 story. Defense is ~30–35% of revenue (~$2bn); the unmanned line (~$500M and growing fastest) spans the Black Hornet PRS nano-UAV, Rogue 1 loitering munition at full-rate production, counter-UAS, EW and maritime surveillance, plus SDA/“Golden Dome” space-sensor wins. This is the genuinely new, demand-led, high-margin leg.
2. Industrial short-cycle recovery. Machine vision, X-ray, MEMS (+~20%) and test & measurement inflecting off a 2023–24 trough — real but cyclical mean-reversion, not secular acceleration.
3. Test & measurement content cycle. PCIe Gen6 and 800G/1.6T optical-networking test refresh should lift the LeCroy lines through 2026–27.
4. M&A conversion. Pre-deal net leverage is about 1.1x and TTM FCF $1.14B. The Varex agreement now converts optionality into a concrete integration test; further large deals should wait until this one closes and cash conversion is visible.

Verdict — mixed-quality growth, defense-led but structurally M&A-dependent. The durable, high-return organic algorithm is only ~4–5%, and much of the multi-year top line has been bought, not grown. The 2025–26 defense/unmanned/space inflection is real, organic and high-margin — genuinely positive — but it is partly exogenous (rearmament, Golden Dome) and not yet proven durable across a full cycle. High-quality segments, average-quality aggregate: low-to-medium-quality growth.

6. Financial Quality

First-half 2026 update. The current numbers are better than the FY2025 base and largely cash-backed, based on the Q2 Form 10-Q and earnings release.

Q2 itself was stronger than the half: $315.2M of operating cash flow and $284.7M of free cash flow against $251.7M of net income. Working capital still deserves attention—management built inventory to protect programs exposed to germanium and rare-earth restrictions—but there is no widening gap between earnings and cash at TDY. The contrast with Varex is material: Varex generated only $3.4M of operating cash and spent $25.9M on capex in the first nine months of FY2026 after a $53.4M inventory build. The target’s weak conversion is either an integration opportunity or evidence that the low acquisition multiple is deserved.

Normalize the tariff refunds before calling Q2’s margin repeatable. Teledyne’s Digital Imaging adjusted margin reached 25.0%, up about 353bp, but management attributed approximately $10M—or about 120bp—to a net tariff refund. Underlying improvement was still more than 200bp, supported by volume and mix, so the quarter was not an accounting mirage. Varex separately recorded about $10M of net IEEPA-tariff benefit in its latest quarter. Both buyer and target therefore contain nonrecurring tariff assistance in the same period; any pro-forma margin model should remove both.

Contract-estimate revisions are the second normalization. Cost-to-cost programs recorded $22.4M of favorable estimate-at-completion profit in the first half versus $1.9M a year earlier. Q2’s approximately $14.2M year-over-year swing explains about 26% of the consolidated increase in operating income. These revisions are normal accounting when expected costs improve, but the historical series—$26.8M favorable in FY2021, $29.9M in FY2022, $3.7M in FY2023, $2.5M unfavorable in FY2024, $12.7M favorable in FY2025—shows why they should not be annualized. Management did not specify whether every “other one-time” element in the Digital Imaging margin bridge overlaps the estimate revisions. Removing only the tariff pickup leaves more than 200bp of segment expansion; removing both effects directionally leaves closer to 75bp, subject to overlap. A range is more honest than double-counting two potentially overlapping adjustments.

Updated liquidity. Teledyne repaid $450M of debt in Q2, leaving $2.039B of carrying-value debt and $340.1M of cash at June 28, or roughly $1.70B of net debt. Management reported 1.1x leverage, and $1.6B remained under the $2B repurchase authorization. A debt-funded $1.1B Varex purchase would take simple pro-forma net debt to roughly $2.8B before intervening free cash flow and transaction adjustments. Against approximately $1.65–1.70B of combined annual EBITDA, that suggests leverage near 1.6–1.7x—an analytical estimate, not company guidance. Financing risk is low; return risk is the relevant constraint.

Revenue quality. As Section 5 shows, Teledyne is a low-single-digit organic grower wearing an acquisition-fed top line; the FY2025 +7.9% is overwhelmingly Qioptiq. That composition is the reason reported returns sit near the cost of capital.

Margin trajectory — real lift since FLIR, now flattened. Gross margin expanded ~290bps (39.9%→42.8%) and operating margin ~530bps (13.5%→18.8%) from FY2021 to FY2025; EBITDA margin 21.6%→24.3%. Some of the FY2021 depression was the partial-year FLIR drag and purchase-accounting step-ups, but the multi-year climb is genuine integration synergy plus mix. Crucially, margins are essentially unchanged FY2023→FY2025 (43.3%/18.4% → 42.8%/18.8%) — the easy post-FLIR harvest is largely done; further margin gains must come from mix (defense, T&M recovery) and fresh deal-optimization.

Cash generation — the genuine strength.

FY2022’s 0.50x conversion was a working-capital air-pocket (inventory −$155M, payables −$298M), not structural. FY2024–25 FCF of ~$1.1bn/$1.07bn converts at 1.2–1.35x of net income — structurally helped by the ~$217M of non-cash amortization that depresses reported net income but not cash. FY2026 guidance is >$1.0bn FCF (management aspires to ~$1.1bn) with CapEx rising to ~$150M from an $84–117M base (still <2% of sales). This is a low-capital-intensity compounder at the cash level.

Share count and SBC — clean and non-dilutive. SBC is trivial for a $6bn tech-industrial — $39.6M in FY2025, ~0.65% of revenue — versus $1.07bn of FCF; there is no SBC-flattered-FCF problem here (contrast software peers). Diluted share count has drifted down: 47.7M (FY22) → 47.4M (FY25) → 46.8M in Q1-2026, as buybacks now exceed dilution. A clean equity story.

ROIC and the goodwill problem — the skeptical crux. Reported returns are mediocre for a “quality compounder”: FY2025 ROIC ~7.4% (NOPAT ≈ EBIT $1,149.8M × (1−18.2%) ≈ $940M over ~$12.8bn invested capital), barely covering an estimated ~8% WACC; filing-derived FY2025 ROE is about 8.9%, not the 13.3% previously reported. TTM ROIC is about 7.8%, or 7.6% after the identified earnings normalizations. The reason the numbers look pedestrian while the underlying businesses are excellent is goodwill and acquired intangibles from 25 years of dealmaking: $10,787.7M, or 70.6% of total assets, exceeding the entire $10,513.9M of book equity — so tangible book equity is negative (≈ −$274M; −$5.93/share) and P/TBV is meaningless. Back out the intangibles and tangible ROIC is ~45%+: the operating businesses are genuinely high-return; the gap between ~45% tangible and ~7.4% reported ROIC is the acquisition premium Teledyne has paid. The negative tangible book is not a distress signal (it is normal for a serial acquirer) — it is a valuation signal: you are buying a portfolio marked at acquisition cost, and the marginal deal must clear a high bar to add value.

Quality of earnings — three flags.

1. GAAP-to-non-GAAP bridge is mostly amortization. GAAP diluted EPS was $18.88 (FY25) / $17.21 (FY24) / $18.49 (FY23). The ~$3–4 gap to management’s non-GAAP figure is almost entirely acquired-intangible amortization: $216.6M in FY2025 (≈$3.5–3.7/diluted share after tax). The add-back is non-cash and real — but it is also recurring and only slowly declining (scheduled $219.1M in 2026 down to $138.8M by 2030) and is refreshed upward by every new deal. Treat non-GAAP EPS as a legitimate cash proxy, not as evidence the charge is a one-time item.
2. Effective tax-rate volatility. The rate swung from 7.5% (FY23) → 12.5% (FY24) → 18.2% (FY25), driven by reversals of unrecognized tax benefits (large in FY23, smaller in FY25) plus a ~$30M FY25 cash-tax cut from the July-2025 tax act. FY2023’s ~$18.49 EPS was flattered by ~$1.90 of tax artifact; FY2025’s 18.2% is the cleaner baseline. Q1-2026 again carried an $8.0M discrete benefit (~$0.17/share). Normalize the tax line before drawing EPS-trend conclusions.
3. Working capital. Inventory rose to $1,043.3M (+14%, faster than +7.9% sales; partly acquired); the cash-conversion cycle stretched to ~113 days from ~79 in 2021. A mild watch-item, not alarming; accounting is otherwise conservative (no capitalized-software games).

Balance sheet — de-levered fortress. Net debt fell from $3.6bn (FY21) to ~$2.29bn (FY25): net leverage ~1.5x (a five-year low), EBITDA/interest ~25x. Debt is $2,489.0M of fixed-rate senior notes on a laddered schedule ($450M 2026, $700M 2028, $427M 2030, $911M thereafter), plus a fully-undrawn $1.20bn revolver. In FY25 Teledyne opportunistically retired $177.0M of its own notes at a discount for a $15.0M gain — a small, shareholder-friendly signal. Ample dry powder for the next deal.

Verdict — economics improve with scale at the operating level, only marginally at the shareholder level. A high-return operating engine (tangible ROIC ~45%, FCF ~$1.07bn at 1.2x conversion, non-dilutive, margin-rich, fortress balance sheet) is bolted to a merely-average capital-return profile: TTM reported ROIC about 7.8%, or about 7.6% normalized—still near WACC, because nearly all the excess return has been capitalized into $10.8bn of goodwill (70.6% of assets; negative tangible book). Scale has grown absolute FCF; per-dollar-of-invested-capital economics have not improved.

7. Capital Allocation

Varex: the first consequential Bobb-era test

On August 10, Teledyne signed a definitive agreement to acquire Varex for $18.90 per share in cash, approximately $1.1B including equity awards and Varex net debt as of April 3. The boards approved it unanimously; Varex shareholder and regulatory approvals remain outstanding, and closing is expected in early 2027. Until a proxy supplies the deal background, competing bids, banker analyses and detailed synergy case, the correct analysis is preliminary.

The entry multiple is the central positive. Teledyne is buying at less than half its own 18.8x enterprise multiple and below the mid-teens prices common for quality instrumentation assets. The strategic logic also holds: Teledyne already makes low-dose CMOS X-ray detectors and magnetrons but not the radiography, fluoroscopy and CT tubes that define Varex; Varex brings X-ray sources, high-radiation flat-panel and photon-counting detectors, high-voltage interconnects and imaging software. Its installed-base replacement profile is better than a one-time equipment sale.

The bear case lives in cash conversion and customer power. Varex’s latest-quarter Medical revenue fell to $134.0M from $142.1M, while Industrial rose to $76.5M from $60.9M. Inventory reached $347.1M, and first-nine-month free cash flow was approximately negative $22.5M after a $53.4M inventory build. Top-ten customer concentration is 52%; China represented $33.1M of the latest quarter; and limited-source inputs plus medical-device requalification slow any supply-chain changes. Teledyne may be buying a genuine moat cheaply, but it is also buying a working-capital problem, a declining medical segment and more trade-policy exposure.

The transaction therefore partly activates but does not confirm the prior bear test. It is large, yet not richly priced on disclosed results. The decisive post-close scorecard should be: Varex organic Medical revenue; inventory and cash conversion; underlying EBITDA excluding tariffs and purchase accounting; integration cash costs; and incremental after-tax operating profit divided by total consideration plus required working capital. EPS accretion alone is insufficient because cheap debt and amortization add-backs can manufacture it.

The M&A engine is the capital-allocation story. Teledyne is, functionally, a diversified serial acquirer in the Danaher/Roper mold — ~75 acquisitions over ~25 years for ~$12.8bn (~$10.8bn cash, ~$4bn stock). The method: buy niche #1/#2 sensor/instrumentation/imaging businesses, integrate onto shared overhead, apply operational-effectiveness programs, expand margins, redeploy the cash. FY2025 alone deployed $821.4M — led by Excelitas/Qioptiq (~$702.8M, aerospace/defense optics), plus bolt-ons Micropac (Dec-24), Adimec (Mar-25), TransponderTech from Saab (Nov-25) and DD-Scientific (Jan-26).

Discipline check — real on leverage, average on aggregate returns. The stated philosophy (Mehrabian’s oft-repeated line that Teledyne “will not pay outrageous prices”) is partially corroborated: FY2022–2024 acquisition spend was deliberately throttled to $78–124M/yr while the company paid down FLIR debt rather than chase deals into a high-multiple market — genuine counter-cyclical restraint. The Qioptiq deal re-opened the wallet only once the balance sheet was repaired. But the ~7.4% group ROIC is itself the scoreboard: disciplined on the price of any single deal, the aggregate multiple paid over 25 years still leaves little excess return for the equity buyer.

FLIR retrospective — the defining decision. The ~$8.0bn FLIR acquisition (closed May 2021, ~$4bn debt-funded) is the deal to judge management on, and the evidence is mixed-to-favorable. Favorable: FLIR is why Digital Imaging is a $3.2bn segment and why group EBITDA margin climbed ~270bps; the debt was fully retired within ~3 years; no impairment of the FLIR core has been taken. Skeptical: ~$8bn was paid at roughly mid-teens EV/EBITDA for a business whose organic growth has since been low-single-digit, and the deal did not lift group ROIC above WACC. A competent, well-integrated, well-financed acquisition of a good asset at a fair-to-full price — value-neutral-to-modestly-accretive, not a home run.

Buybacks now the swing use of cash; no dividend. With leverage repaired, capital return has stepped up: buybacks of $402.9M (FY25) and $354.0M (FY24) — enough to shrink the diluted count. In July 2025 the Board authorized a new $2.0bn repurchase program (no expiration; ~$1.96bn remained at year-end after buying ~577k shares at ~$505–524 in Q4). Repurchasing near record levels is programmatic return of excess FCF — acceptable, but not opportunistic value-buying. No dividend, and none contemplated (10-K, verbatim) — reasonable for a compounder, but it means the entire shareholder return depends on capital-allocation skill (deals + buybacks) rather than a cash yield.

R&D / opex intensity. Company-funded R&D of ~$317.3M (~5.2% of sales) is down from $356.3M (FY23) — moderate for the sector; Teledyne buys technology more than it invents it. SG&A ~$931M (15.2% of sales). Well-controlled.

Incentive alignment — sound, but no capital-return gate. The 2026 proxy metrics are operationally reasonable but omit an explicit ROIC/return-on-capital gate — a notable gap given the group-ROIC-near-WACC problem. The Annual Incentive Plan weights 40% adjusted pre-tax income, 25% adjusted revenue, 15% managed working capital, 20% individual — it pays for working-capital discipline but not for margin or capital efficiency, and “adjusted” earnings/revenue can be grown by acquisition. The 2025–2027 long-term cash plan weights cumulative adjusted pretax income 40%, cumulative revenue 30% and relative TSR 30%; performance RSUs depend solely on relative TSR. Acquired revenue and pretax income count, so the scorecard can reward transaction size without directly charging for purchase price. Say-on-Pay approval was 95.6%.

Governance flag — the Executive Chairman. Robert Mehrabian, who ran Teledyne as CEO for two decades, remains Executive Chairman and was the highest-paid executive at $9,787,488 in FY2025 — more than double new CEO George Bobb III’s $4,255,049. Bobb was promoted to President & CEO on April 28, 2025, succeeding Edwin Roks (who departed with $1.8M severance). Paying a non-CEO Executive Chairman the single-largest package signals Mehrabian still holds the reins — a real succession/key-person overhang on the one skill this model depends on. Insider alignment is otherwise modest: all directors and officers own just 1.3% of the class (Mehrabian 200,722 shares / ~0.43%; Bobb 26,572), and the full five-year Form 4 corpus shows one open-market purchase—Stephen VanWees bought about $639,000 in September 2021—plus substantial code-S sales. Since the prior report, directors Simon Lorne and Wesley von Schack sold about $4.71M combined without 10b5-1 plans; the current signal is modestly negative but not C-suite selling.

Verdict — a good, disciplined allocator running an average-return model. Management de-levered a large deal in three years, restarted count-shrinking buybacks, retired debt at a discount, pays no wasteful dividend, and runs plans that paid below target when performance lagged — above-average stewardship. But the ultimate scoreboard — ~7.4% group ROIC after 25 years and ~$12.8bn of deals — says capital has been allocated competently rather than brilliantly: value preserved and compounded in absolute cash terms, not multiplied per dollar of capital. The plans reward acquired growth without a capital-return gate, and a ~$9.8M Chairman above the CEO is a legitimate mark-down. Not a top-tier Roper/Danaher value-creation machine.

No shares were repurchased in the first half of 2026; Teledyne instead used cash to repay $450M of debt and rebuild capacity ahead of Varex. At June 28, $1.6B remained on the authorization. That ordering is rational: acquiring an adjacent business near 9x normalized EBITDA is more attractive than repurchasing TDY near 19x, provided Varex earnings convert to cash. The transaction will probably postpone repurchases while leverage normalizes.

8. Changes and Headwinds — Last Two Years

The two events since the prior report dominate the update:

1. Q2 beat-and-raise. Revenue, orders, margins, EPS and free cash flow all set or approached records. The guide moved higher across sales and both GAAP and adjusted EPS. This confirms that the first-quarter acceleration was not a one-quarter artifact.
2. Varex agreement. A roughly $1.1B transaction is large enough to matter but priced at about 8.9x trailing adjusted EBITDA, or roughly 9.7x after removing the disclosed Q3 tariff benefit. It adds installed-base economics and X-ray-source capabilities while importing weaker cash conversion, medical-volume pressure, China exposure and customer concentration.

Three less visible headwinds belong beside them. First, favorable changes in estimates-at-completion on long-term contracts added $22.4M of pretax income in the first half versus $1.9M a year earlier. The filing does not map that benefit cleanly by segment, but it represented roughly 26% of the year-over-year increase in Q2 operating profit. That is legitimate contract accounting as cost expectations improve, yet not the same quality as price or volume and may not recur.

Second, more than $1B of annual revenue depends on germanium and/or rare-earth magnets. Management has spent more than a year building mitigations—including recovering and machining germanium scrap—but did not disclose inventory coverage, dual-source percentages or price-pass-through rights. China’s export-license regime therefore remains a measurable exposure without a measurable cushion.

Third, the Bureau of Industry and Security’s February 26 final order imposed a $1M civil penalty on Teledyne FLIR for conduct underlying 19 Export Administration Regulations violations. Most conduct predated Teledyne’s 2021 acquisition, but eight exports to an Entity List address occurred in 2024 and were voluntarily disclosed after discovery in February 2025. The dollar amount is immaterial; the post-acquisition incidents show that compliance integration is not risk-free. See the BIS final order.

1. CEO transition (the governance asterisk). Mehrabian — the architect of the entire roll-up era — stepped back to Executive Chairman; George Bobb III became President & CEO (April 28, 2025), and Edwin Roks departed. This is the single largest governance change in the company’s modern history. Mehrabian was the capital-allocation engine, and the market is paying a re-rated multiple partly on the assumption that the acquisition machine runs unchanged without its founder-operator — unproven. His retained Executive-Chairman role (and top-of-table pay) mitigates but also muddies the new-CEO mandate.
2. The 2024–26 acquisition string. Continued bolt-on cadence (Micropac, Adimec, Qioptiq, TransponderTech, DD-Scientific) culminated in the announced $1.1B Varex transaction. FY2026 guidance now implies nearly 7% reported growth, with only modest acquisition contribution before Varex closes. The de-levered balance sheet is dry powder to the bull and pressure to deploy to the bear — a serial acquirer with cash and a 7.4% incremental ROIC is exactly where capital-cycle discipline is most tested.
3. Defense inflection (the clear positive). Book-to-bill >1 for eleven straight quarters, more than $5bn of remaining performance obligations, and drone/counter-drone/space wins — the strongest fundamental development in years and the proximate cause of the 2026 re-rating.
4. China / export-control / germanium supply chain (a live headwind). Teledyne’s IR/imaging businesses depend on germanium and other China-restricted materials; management is building inventory to buffer supply (a working-capital and FCF-conversion drag). Dual-use controls cut both ways — gating input access and restricting sales into China.
5. Fading FX tailwind. A meaningful slice of 2025’s reported strength was currency (large European/FLIR/Qioptiq footprint); management guides FX benefit toward zero in H2-2026. A reason to discount the headline growth toward the mid-single organic core.
6. Industrial short-cycle recovery (cyclical positive). Test & measurement, machine vision, MEMS and X-ray inflecting off trough — real but cyclical, improving the 2026–27 setup without changing the structural algorithm.

Verdict — net slightly thesis-strengthening, with a governance asterisk. The defense/unmanned/space inflection and the de-levered balance sheet strengthen the near-term thesis; the CEO transition, germanium/export-control exposure, fading FX and the ever-present pressure to keep acquiring at marginal returns are real offsets. On balance the last two years improved the business. Since July, results and guidance improved while the price fell, leaving a more balanced valuation; Varex makes execution and capital returns the new center of the debate.

9. Risk Analysis

The stacked downside. The realistic adverse path is not one product failure. Defense orders normalize, critical-input inventories absorb cash, estimate benefits reverse, and Varex’s Medical decline takes longer to repair. EBITDA growth slows just as leverage rises and the multiple compresses from a quality-compounder level. Each event is survivable alone; together they can create several years of poor equity returns even while the company remains profitable.

Risk mitigants. Four segments, broad geography, long program lives and low standalone capex reduce business fragility. TTM free cash flow of $1.142B covers current interest many times over; pre-deal net leverage is about 1.1x and illustrative post-deal leverage only around 1.6x. Varex’s installed base produces replacement demand, and the 8.9–9.7x entry multiple creates room for imperfect execution. The existing $5.18B performance obligation base also makes an abrupt revenue collapse unlikely absent cancellations.

Catastrophic loss. The probability of total loss is very low. TDY is investment-grade, diversified and self-funding; even a poor Varex outcome would be about 4% of pro-forma enterprise value, not an existential bet. Permanent impairment is more plausibly caused by repeated acquisitions below the cost of capital than by insolvency. Investors should therefore distinguish business survival risk, which is low, from duration and multiple risk, which is material.

What would change the matrix quickly: a second large acquisition before Varex closes would raise leverage and execution risk; two consecutive book-to-bill readings below 1 would raise demand risk; quantified non-China critical-material coverage would lower supply risk; and Varex free-cash-flow conversion above net income would lower integration risk. Those are observable milestones rather than generic uncertainty.

10. Valuation Discussion (Embedded Expectations)

The valuation reset is real, but “cheaper” is not “cheap.” At the September 2 close of $606.36 and 46.329M shares, market capitalization is $28.092B. Adding $1.687B of June net debt gives a manually rebuilt enterprise value of $29.779B. Using trailing-twelve-month results through Q2—$6.374B revenue, $1.582B EBITDA, $974.8M GAAP net income and $1.142B free cash flow—produces the following current snapshot:

The normalization removes excess favorable contract-estimate revisions and the disclosed tariff pickup, using filing-derived approximations. It is directionally important but not an audited alternative measure, especially because the company has not clarified overlap between “other one-time” items and estimate-at-completion effects.

Own history says normal-to-high rather than extreme. AZI’s September 2 valuation series reports 28.89x TTM P/E at the 53.8th percentile of TDY’s own history, 4.42x P/S at the 79.9th percentile and a composite at the 57.1st percentile. Since the July memo, those percentiles fell by roughly 23, 13 and 16 points, respectively. This resolves the earlier tension: the stock is no longer a near-peak valuation on a broad composite, although sales remain richly capitalized because margins and cash generation are near records. The improvement came from both a 7% price decline and higher trailing earnings.

Peer calibration. A manually rebuilt September 2 peer snapshot—current equity value plus latest reported net debt, divided by trailing results—avoids stale enterprise values:

TDY is now the cheapest member of this selected group on EBITDA and sales, but not obviously mispriced because its reported ROIC is also inferior to AMETEK, Curtiss-Wright and Agilent. Danaher shows that low reported ROIC can coexist with a premium when recurring revenue quality is higher. Teledyne’s discount is therefore partly earned. AMETEK remains the hardest comparison: investors pay roughly four more EBITDA turns for about five additional points of ROIC. The difference is less damning than it was in July because TDY’s multiple fell and its organic growth accelerated.

Varex is mildly multiple-accretive before any synergy. Simply adding the $1.1B stated transaction value and Varex’s $865M TTM revenue/$123M adjusted EBITDA to current TDY yields illustrative combined EV of $30.879B, sales of $7.239B and EBITDA of $1.705B. Those translate to about 4.27x sales and 18.11x EBITDA, with pro-forma net leverage around 1.64x before fees, financing refinements, intervening cash flow, synergies or purchase accounting. Normalizing Varex’s tariff benefit lifts the combined EBITDA multiple modestly. The bridge shows why the deal can create value, not that it will: it buys earnings below TDY’s multiple, but actual incremental ROIC depends on cash conversion and integration capital.

Embedded expectations. A 4.07% trailing FCF yield against an 8–9% cost of capital requires meaningful growth. In a simple steady-state frame at 8.5% cost of capital, the current enterprise value is consistent with approximately 4.2% perpetual free-cash-flow growth. That is close to Teledyne’s historical organic algorithm and therefore not fantastical. The hidden assumption is reinvestment quality: if growth continues to rely on acquisitions earning roughly 7–8%, it adds scale without much economic profit. If the first-half 7–9% organic pace persists and incremental margins remain high, more of the growth comes from existing intangible assets and the valuation becomes easier to defend.

Three-year scenario frame—illustrative expectations, not a target.

The bear case does not require a recession or program cancellation. It requires only normalization from a high order cycle plus an integration that consumes cash. The base case assumes neither the current first-half growth rate nor the July peak multiple persists indefinitely. The bull case requires the event the company has not delivered since FLIR: organic growth plus a large acquisition jointly lifting reported returns on capital.

Valuation verdict. TDY is materially better priced than in July and modestly discounted to quality peers, but the 4.1% cash yield and 7.6–7.8% return on invested capital leave limited room for execution errors. Current expectations are achievable if organic growth normalizes around 5% and Varex is competently integrated. They become attractive only if the growth mix becomes more organic and returns move away from the cost-of-capital boundary. The multiple is no longer the thesis’s primary defect; capital productivity is.

11. Variant Perception

The consensus-shaped narrative. Teledyne is commonly treated as a scarce, lower-volatility way to own several favored themes at once: defense electronics, unmanned systems, counter-UAS, space sensing, subsea autonomy and high-end instrumentation. The factual support is now strong—record orders, eleven quarters of book-to-bill above 1, broad organic growth and raised guidance. The market’s error is less likely to be direction than attribution: a sector-wide upcycle can look like company-specific share gain, and favorable contract revisions can look like permanent margin.

The strongest bull case. TDY owns qualification-heavy sensor and instrument franchises that cannot be cheaply replicated by low-cost labor. Space and defense programs have long lives; FLIR’s installed base and Teledyne’s detector process knowledge are difficult to displace; test and marine products sit inside customers’ workflows and platforms. First-half organic growth around 7.8%, $5.18B of remaining performance obligations and underlying Digital Imaging margin improvement indicate that acquired assets are finally producing internal growth. Varex adds a regulated replacement base at a price below 10x normalized EBITDA. If Teledyne applies its operating system without losing customers, it can turn a lower-quality target into higher-return growth and disprove the “bought-not-built” critique.

The strongest bear case. This is still a hardware federation earning approximately 7.6% normalized ROIC, with goodwill and acquired intangibles dominating invested capital. The broad defense/test/imaging cycle is favorable for nearly every peer, so current growth may say more about end markets than moat share. Roughly a quarter of Q2 incremental operating profit came from favorable contract-estimate revisions, Digital Imaging received a tariff refund, and Instrumentation margin fell even as defense/autonomy sales rose. Varex adds a declining Medical segment, weak cash conversion, customer concentration and China risk. At roughly 19x EBITDA and 25x free cash flow, “competent” execution is already required.

The variant view. The market appears too binary about Varex. Deal size alone caused concern because it resembles the opening move of another acquisition cycle, yet the disclosed price is the opposite of reckless: about 9.7x normalized EBITDA. Conversely, a low multiple does not make it automatically accretive to intrinsic value. The most useful variant is to separate entry discipline from post-close return. Entry discipline looks good; post-close working-capital and margin conversion are unknown. That makes Varex a testable two-year operating thesis rather than an immediate verdict on management.

Momentum and factor positioning. The price action has cooled sharply. At $606.36, TDY sat 5.5% below its 21-day EMA, 5.9% below its 50-day and 1.4% below its 200-day; the 50-day remained above the 200-day. Raw adjusted-price returns were approximately -1.9% over three months, -11.2% over six months and +12.7% over twelve months. The prior one-way momentum regime has therefore softened, not collapsed.

FactorsToday’s base model assigns modest positive Momentum and Quality exposures, but the broader model reduces both close to zero after industrial and other factors are included. R-squared is 0.438 and stock-specific annualized volatility 19.3%, leaving more than half of variance unexplained. Related exposures cluster most closely with defense and industrial ETFs, while the industrial factor itself has recently been weak but not at a two-standard-deviation extreme. Interpretation: the stock has shed crowded momentum, yet it is not a factor-capitulation trade. Fundamentals and Varex-specific news should dominate the next leg.

The five assumptions that matter:

1. First-half organic growth settles above the historical 3–5% rate rather than returning fully to it.
2. Funded defense and space programs convert backlog to revenue without adverse mix.
3. Varex’s installed-base captivity outweighs customer concentration and vertical integration.
4. Inventory and operating cash conversion normalize after close.
5. Incremental returns rise even though compensation plans reward revenue and adjusted pretax income without an explicit ROIC gate.

Falsification map. The operating bull view fails if organic growth falls below 4% while peers continue growing faster, showing weak relative execution; it strengthens if TDY sustains 6% or better across at least four more quarters without relying on acquisitions. The capital-allocation bull view fails if pro-forma ROIC falls or Varex remains free-cash-flow negative after integration; it strengthens if Varex produces double-digit incremental after-tax returns on total invested capital. The order-book bear view fails so long as book-to-bill remains above 1 and backlog grows; it becomes relevant only after two sub-1 quarters or material program cancellations.

Verdict: The variant opportunity improved because price and expectations normalized while operating evidence strengthened. The remaining debate is unusually clean: whether higher organic growth and a low-multiple acquisition can lift consolidated returns. Until the ROIC answer appears, TDY is a better operating story than a proven value-creation story.

12. Fact vs. Interpretation Table

The distinction between accounting fact and investment interpretation is especially important in three places. Record orders establish demand, not permanent market share. A low Varex multiple establishes entry discipline, not value creation. And high tangible operating returns establish valuable franchises, not high returns on the acquisition prices shareholders actually funded.

13. Open Questions

1. Organic duration: Does growth remain at or above 6% through 2027 after easy comparisons and current defense urgency normalize?
2. Share versus cycle: Can management provide program wins, customer additions or comparable market denominators showing share gains rather than mere participation in a broad upcycle?
3. Varex normalized earnings: What are cost synergies, integration costs, purchase-accounting amortization and a clean EBITDA base excluding tariff refunds?
4. Varex cash conversion: How quickly can $347M of inventory normalize, and what permanent working-capital intensity should investors assume?
5. Medical growth: Why is Varex Medical revenue declining, and what portion reflects customer inventory, China localization, price, lost share or product transition?
6. Incremental ROIC: Will management disclose return-on-invested-capital or economic-profit thresholds for Varex and future acquisitions rather than only EPS accretion?
7. Critical inputs: For the more-than-$1B germanium/rare-earth-dependent revenue pool, what percentage has qualified non-China supply, customer-furnished material, price pass-through and more than twelve months of coverage?
8. Contract estimates: Which programs generated the first-half estimate-at-completion benefit, and how much of the Digital Imaging margin bridge overlaps the tariff/“other one-time” explanation?
9. Succession authority: How are acquisition decisions divided between CEO George Bobb and Executive Chairman Robert Mehrabian, and when does the transition become unambiguous?
10. Capital returns: With Varex ahead, are buybacks paused until leverage falls to a defined level, and what repurchase valuation discipline governs the remaining $1.6B authorization?
11. Export compliance: What control changes followed the 2024 exports cited in the BIS order, and have audits identified any similar post-acquisition gaps?
12. Installed-base economics: What percentage of Varex revenue is true replacement/service demand versus new-system OEM production, and what are the respective margins?

These are answerable questions with observable outputs. The most important are incremental ROIC and Varex cash conversion because they distinguish inexpensive acquisition accounting from genuine shareholder value creation.

14. What Must Be True

For the favorable operating case to hold: Teledyne must sustain organic growth around 6% or better across multiple segments for at least four more quarters; book-to-bill must remain near or above 1; and the backlog must convert without Instrumentation-style adverse mix. Digital Imaging margin should remain materially above its 2025 level after tariff benefits and favorable contract revisions normalize. Evidence so far is supportive, not conclusive.

For Varex to create value: normalized target EBITDA must be at least around the current $110–125M range; Teledyne must release or earn an adequate return on Varex’s working capital; Medical revenue must stabilize; and integration costs must not consume the apparent purchase discount. On a roughly $1.1B total price, an incremental after-tax operating return above 10% would be persuasive; a persistent return below Teledyne’s cost of capital would show that the low multiple was a value trap. This is an analytical hurdle, not company guidance.

For the negative case to hold: defense and space growth must normalize toward the old 3–4% organic algorithm; estimate revisions and tariffs must explain more of current profitability than volume/mix; and the market must continue paying a quality multiple despite consolidated returns near the cost of capital. The share-price risk is then a double hit—slower earnings plus multiple compression—rather than solvency.

Explicit falsification tests:

The prior bear trigger on orders is emphatically unhit: Q2 book-to-bill was 1.23 and orders have exceeded sales for eleven quarters. The prior bull trigger on growth is tracking but lacks duration. The ROIC trigger remains unhit. The acquisition trigger is the nuanced one: a large deal arrived, but the “richly priced” requirement did not. Post-close economics will decide it.

15. Public Source Appendix

Primary filings and company materials carry the quantitative analysis; third-party datasets are used only for price, factor and reconciled trailing-series context.

Teledyne primary sources

• Teledyne Technologies FY2025 Form 10-K — SEC, filed 2026-02-20, annual report. Competition, segments, acquisition history, financial statements, goodwill, debt, tax and risks. Document
• Teledyne Q1 2026 Form 10-Q — SEC, filed 2026-04-24, quarterly filing. Q1 financials and contract-estimate revisions. Document
• Teledyne Q2 2026 earnings release — Teledyne/SEC, published 2026-07-22, earnings release. Results, guidance, segment performance and cash flow. Document
• Teledyne Q2 2026 Form 10-Q — SEC, filed 2026-07-24, quarterly filing. Financial statements, RPO, segment results, debt, estimate revisions and trading-plan disclosure. Document
• Teledyne investor events archive — Teledyne, Q1/Q2 2026 events, earnings-call audio and presentation index. Page
• Teledyne 2026 definitive proxy — SEC, filed 2026-04-24, governance and compensation filing. Incentive metrics, ownership and executive pay. Document
• Teledyne FLIR final order — U.S. Bureau of Industry and Security, dated 2026-02-26, enforcement order. PDF
• Director Simon Lorne Form 4 — SEC, filed 2026-08-12, insider transaction. XML
• Director Wesley von Schack Form 4 — SEC, filed 2026-08-13, insider transaction. XML

Varex transaction and target sources

• Teledyne to acquire Varex Imaging — Teledyne/Varex, filed and published 2026-08-10, transaction announcement. Terms and product fit. Document
• Agreement and Plan of Merger — SEC, filed 2026-08-10, definitive agreement. Conditions, termination provisions and representations. Document
• Varex FY2025 Form 10-K — SEC, filed 2025-11-17, annual report. Installed base, replacement cycles, customers, competition, risks and results. Document
• Varex Q3 FY2026 preliminary results — Varex/SEC, published 2026-08-10, earnings release. Segment revenue, adjusted EBITDA, cash flow and tariff benefit. Document
• Varex Q3 FY2026 Form 10-Q — SEC, filed 2026-08-12, quarterly filing. Customer/geographic concentration, inventory, debt, supply and regulatory risks. Document

Government and industry-cycle sources

• FY2026 defense-budget briefing — U.S. Department of Defense, published 2025-06-26, budget overview. Page
• FY2027 Space Force budget request — U.S. Space Force, published 2026-04-21, budget release. Page
• Defence Readiness Roadmap 2030 — European Commission, updated 2026-08-20, policy roadmap. Page
• Rare-earth export controls, Announcement No. 18 — China Ministry of Commerce, effective 2025-04-04, regulatory announcement. Page
• Export Administration Regulations Parts 740 and 742 — U.S. Bureau of Industry and Security, current rules accessed 2026-09-03. Part 740; Part 742
• AMETEK Q2 2026 results — SEC exhibit, filed 2026-08-04, primary peer earnings release. Document
• Cognex Q2 2026 results — SEC exhibit, filed 2026-08-05, primary peer earnings release. Document
• Keysight Q3 FY2026 results — SEC exhibit, filed 2026-08-18, primary peer earnings release. Document
• Leonardo DRS Q2 2026 results — SEC exhibit, filed 2026-07-29, primary peer earnings release. Document
• Curtiss-Wright Q2 2026 results — SEC exhibit, filed 2026-08-05, primary peer earnings release. Document

Market and analytical datasets

• TDY adjusted daily price history — AZI Trading, downloaded 2026-09-03, five-year prices and event-map calculations. CSV
• TDY valuation index — AZI Trading, accessed 2026-09-03, own-history P/E, P/B, P/S and composite percentiles.
• TDY factor loadings, stock-specific volatility and related stocks — FactorsToday, accessed 2026-09-03, empirical risk model. Methodology
• Competition Demystified — Bruce Greenwald and Judd Kahn, 2005, analytical framework.
• Capital Returns — Edward Chancellor/Marathon Asset Management, 2015, analytical framework.

All web sources were accessed on 2026-09-03 unless otherwise stated. Calculated figures identify their inputs in the body; SEC filings control where a third-party series differs.